NasdaqGS:BCYC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Bicycle Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCYC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: BCYC's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

34.3%

BCYC

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

141.3%

BCYC

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: BCYC exceeded the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: BCYC exceeded the US Market which returned 19.6% over the past year.


Shareholder returns

BCYCIndustryMarket
7 Day34.3%3.5%-1.0%
30 Day41.1%4.8%2.3%
90 Day39.8%21.7%13.1%
1 Year141.3%141.3%39.0%36.8%22.3%19.6%
3 Yearn/a30.5%23.6%45.3%35.7%
5 Yearn/a43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Bicycle Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bicycle Therapeutics undervalued compared to its fair value and its price relative to the market?

5.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BCYC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BCYC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BCYC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BCYC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCYC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCYC is overvalued based on its PB Ratio (5.2x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Bicycle Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-10.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCYC's revenue (37.5% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: BCYC's revenue (37.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCYC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bicycle Therapeutics performed over the past 5 years?

-26.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BCYC is currently unprofitable.

Growing Profit Margin: BCYC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCYC is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.

Accelerating Growth: Unable to compare BCYC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: BCYC has a negative Return on Equity (-34.67%), as it is currently unprofitable.


Next Steps

Financial Health

How is Bicycle Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: BCYC's short term assets ($164.2M) exceed its short term liabilities ($17.0M).

Long Term Liabilities: BCYC's short term assets ($164.2M) exceed its long term liabilities ($43.5M).


Debt to Equity History and Analysis

Debt Level: BCYC's debt to equity ratio (13.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BCYC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCYC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BCYC has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 3.2% each year.


Next Steps

Dividend

What is Bicycle Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCYC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCYC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCYC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCYC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCYC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Kevin Lee (51 yo)

5.33yrs

Tenure

US$4,376,297

Compensation

Dr. Kevin Lee, Ph.D. has been Chief Executive Officer of Bicycle Therapeutics Limited since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and Chie...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD4.38M) is above average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Lee
CEO & Executive Director5.33yrsUS$4.38m1.24%
$ 7.2m
Lee Kalowski
President & CFO2yrsUS$2.48m0%
$ 0
Gregory Winter
Co-Founderno dataUS$23.95k0.77%
$ 4.4m
Michael Skynner
Chief Operating Officer5yrsUS$1.82m0.19%
$ 1.1m
Christian Heinis
Scientific Founderno datano datano data
Nicholas Keen
Chief Scientific Officer4yrsno data0%
$ 0
Zafar Qadir
General Counsel0.75yrno datano data
Gillian Langford
Head of Clinical and Project Management4.67yrsno datano data
Rosamond Deegan
President of U.S. and Chief Business Officer of U.S.4.67yrsno datano data
Phil Jeffrey
Senior VP of Pre-Clinical Development2.17yrsno datano data
Nigel Crockett
Chief Business Officer1.33yrsno datano data
Lisa Mahnke
Senior VP & Head of Clinical1.67yrsno datano data

3.1yrs

Average Tenure

51yo

Average Age

Experienced Management: BCYC's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Lee
CEO & Executive Director5.33yrsUS$4.38m1.24%
$ 7.2m
Gregory Winter
Co-Founderno dataUS$23.95k0.77%
$ 4.4m
Catherine Bingham
Independent Non-Executive Director6.25yrsUS$31.43k2.22%
$ 12.8m
Richard Aldrich
Board Observer3.58yrsno datano data
Edward Scolnick
Member of Scientific Advisory Board2.67yrsno datano data
Keith Peters
Chairman of Scientific Advisory Board0.58yrno datano data
Pierre Legault
Non-Executive Chairman1.83yrsUS$2.07m0.73%
$ 4.2m
Veronica Geraldine Jordan
Independent Non-Executive Director1.25yrsUS$179.69k0.11%
$ 624.7k
Richard Kender
Independent Non-Executive Director1.5yrsUS$228.04k0.12%
$ 696.7k
Garret FitzGerald
Member of Scientific Advisory Board0.25yrno datano data
Janice Bourque
Independent Non-Executive Director1.5yrsUS$212.33k0.12%
$ 696.7k
Geoffrey Shapiro
Member of Scientific Advisory Board2.67yrsno datano data

1.8yrs

Average Tenure

65yo

Average Age

Experienced Board: BCYC's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.


Top Shareholders

Company Information

Bicycle Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bicycle Therapeutics plc
  • Ticker: BCYC
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$575.869m
  • Shares outstanding: 21.30m
  • Website: https://www.bicycletherapeutics.com

Number of Employees


Location

  • Bicycle Therapeutics plc
  • Babraham Research Campus
  • Building 900
  • Cambridge
  • Cambridgeshire
  • CB22 3AT
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCYCNasdaqGS (Nasdaq Global Select)YesSPONSORED ADSUSUSDMay 2019

Biography

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicyc...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/19 00:10
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.